HER2+ 유방암 | 바이오모아

AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5

효능 ORR 91.8%임상시험 204상태 DISCONTINUED

AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4

효능 ORR 76.7%임상시험 90상태 ACTIVE

ADCBiologicPfizerderuxtecan and tucatinibPhase 3

Tucatinib (Tucatinib)

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 100%임상시험 57상태 RECRUITING

ADCBiologicstaleShanghai JMT-Bio Inc.Phase 2

KN026 (KN026)

HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 17상태 RECRUITING

CGTBiologicstaleCytoMed Therapeutics Pte LtdPhase 1

Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell (Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell)

Colorectal Cancer; Triple Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Fruquintinib)

HER2; Colorectal Cancer · HER2

#HER2#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab +Cetuximab β+Irinotecan)

HER2 Positive; Colorectal Cancer (CRC) · HER2

#HER2#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

ADCBiologicstaleChia Tai Tianqing Pharmaceutica…Phase 3

Trifluridine /Tipiracil (TAS-102, Trifluridine /Tipiracil, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets)

HER2 IHC3+ Advanced Colorectal Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING